Scinai Immunotherapeutics Ltd. has received clearance from the Italian government under the Golden Power regulation for its potential acquisition of Pincell S.r.l., an Italian biotechnology company. This regulatory approval is a significant milestone, allowing Scinai to advance toward finalizing the transaction, pending remaining conditions. The approval involved a review by the Coordination Group for the exercise of special powers, following an assessment by the Ministry of Health. The acquisition includes a license for Pincell's intellectual property rights. Scinai's Polish subsidiary has also submitted a €12 million grant application under the European Funds for a Modern Economy program to support the development of Pincell's lead candidate, PC111. An award decision is expected by mid-July to early August 2025. Completion of the acquisition is contingent on additional conditions, including the grant's successful outcome.